This study provides a reliable molecular foundation for developing rapid, highly sensitive immunodiagnostic tools against MPXV. The fully human antibody screening strategy employed offers a reproducible technical pathway for designing antigen detection assays against emerging viral pathogens.
Literature Overview
The article 'A Novel Monoclonal Antibody Targeting the A29 Protein of Monkeypox Virus and Its Application in Immunoassay', published in the journal 'Antibodies', systematically investigates the use of the monkeypox virus's key envelope protein A29 as a target. High-affinity fully human monoclonal antibodies were screened using phage display technology and comprehensively evaluated for performance in immunoassays. By combining molecular modeling with functional experiments, the study reveals the binding mechanism and detection potential of antibody D10, providing a new tool for rapid monkeypox virus diagnosis.Background Knowledge
Monkeypox virus (MPXV) has drawn global attention in recent years, posing an ongoing public health threat due to its transmission potential. Current diagnosis primarily relies on PCR detection of MPXV nucleic acid, which, although highly specific, requires specialized equipment and trained personnel, making it difficult to implement in resource-limited or field settings. Therefore, there is an urgent need to develop rapid and user-friendly antigen detection methods. The A29 protein, an envelope protein of the MPXV mature virion (IMV), mediates viral binding to host cells and is an important antigenic target. Due to its low sequence homology within the orthopoxvirus genus, A29 is considered a highly specific diagnostic marker, yet high-affinity, high-specificity monoclonal antibodies are currently lacking. Traditional hybridoma technology relies on animal immunization, which is time-consuming and less suitable for rapidly responding to emerging infectious diseases, and murine antibodies may cause immunogenicity issues. This study uses phage display technology to directly screen anti-A29 antibodies from a human antibody library, bypassing the time-consuming animal immunization process and yielding fully human antibodies—ideal candidates for developing diagnostic reagents with low immunogenicity and high stability.
Research Methods and Experiments
The study used a prokaryotic expression system (E. coli Rosetta (DE3)) to express and purify recombinant A29 protein, with high purity and integrity confirmed by SDS-PAGE. Subsequently, a human Tomlinson I+J phage display library was employed, and three rounds of biopanning were conducted to enrich phage clones specifically binding to A29. After ELISA screening, a clone, D10, exhibiting high specificity for A29 was identified, and sequencing confirmed the uniqueness of its complementarity-determining region (CDR) sequences. To evaluate binding performance, the antigen-binding fragment (Fab) of D10 was expressed and purified. ELISA confirmed that D10 Fab specifically binds to A29 proteins expressed in both prokaryotic and eukaryotic (HEK293) systems, indicating recognition of the native conformation. Further, bio-layer interferometry (BLI) was used to measure the affinity between D10 Fab and A29, yielding a dissociation equilibrium constant (KD) of 6.44 nM, indicating high-affinity binding. Molecular docking simulations predicted the potential binding interface between D10 and A29, involving residues Gln67, Arg74, Asn75, Arg81, Asn84 of A29 and Ser10, Thr5, Gly49, Gly47, Glu97 of D10's heavy chain, suggesting that hydrogen bonds and spatial complementarity play critical roles in binding. Finally, competitive ELISA was used to assess detection performance, yielding a half-maximal inhibitory concentration (IC50) of 1.88 µg/mL and a limit of detection (LOD) of 0.12 µg/mL, demonstrating its potential for quantitative A29 antigen detection.Key Conclusions and Perspectives
Research Significance and Prospects
This study successfully developed a fully human, high-affinity monoclonal antibody D10 targeting the MPXV A29 protein, filling a gap in high-quality antibodies for existing diagnostic tools. Its high affinity and specificity make it an ideal candidate for constructing antigen detection platforms such as ELISA and immunochromatographic strips, potentially enabling rapid, point-of-care testing for monkeypox virus, especially suitable for resource-limited settings. The fully human nature of D10 opens possibilities for future development as a therapeutic antibody, avoiding the complex process of humanization. Additionally, the phage display technology used in this study serves as a paradigm for rapid antibody discovery in response to future emerging infectious diseases. Although current detection sensitivity is not yet on par with PCR, integrating D10 into more sensitive platforms (e.g., fluorescence immunochromatography, electrochemical detection) could further enhance performance. Future work should validate D10's cross-reactivity with A29 proteins from different MPXV strains to assess its breadth.
Conclusion
This study successfully screened and characterized a fully human monoclonal antibody D10 targeting the key antigen A29 of monkeypox virus. Its high affinity (KD = 6.44 nM) and specificity lay a solid foundation for developing novel immunoassay tools. This antibody can be used not only to construct rapid antigen detection platforms to aid in early screening and epidemic monitoring of MPXV, but its fully human nature also opens avenues for potential therapeutic applications. The phage display technology employed demonstrates the capability to rapidly obtain high-quality antibodies in response to emerging infectious diseases, offering a reproducible strategy for future pathogen responses. The development of D10 marks a critical step toward more convenient and reliable monkeypox virus diagnostics, holding significant value for improving MPXV healthcare systems and enhancing public health emergency preparedness. Future efforts should focus on integrating D10 into point-of-care devices and evaluating its performance in real-world samples to accelerate its translation from laboratory to clinical use.
